Paragon Care Limited · ASX:PGC
Paragon Care — Shareholder Meeting (November 2024)
38 slides from Paragon Care's shareholder meeting presentation, Nov 21, 2024
Slide 1: ASX Announcement: 2024 AGM Chair Address and Presentation
1300 369 559 info@paragoncare.com.au paragoncare.com.au ASX ANNOUNCEMENT 21 November 2024 Australian Securities Exchange Company Announcements Office 2024 ANNUAL GENERAL MEETING – CHAIR ADDRESS AND PRESENTATION Paragon Care Limited (ASX:PGC) (“Paragon” or the “Company”) attaches in accordance with A
Slide 2: Chair Address
CHAIR ADDRESS Good afternoon, everyone. My name is Peter Lacaze, the Company’s Chair, and it is my pleasure to welcome you to the Annual General Meeting of Paragon Care Limited (“ParagonCare” or the “Company”). On behalf of the Company, I would like to start by acknowledging the Traditional Owners o
Slide 3: Chair Address (continued): dividend and thanks
It is unlikely that a dividend will be paid this financial year with the focus being on integration, and ensuring we have the right resources to execute our growth opportunities. Our Dividend Policy will be reviewed in FY2026 which again will be subject to our future growth opportunities. I thank al
Slide 4: Annual General Meeting November 2024
Annual General Meeting 21 November 2024 ParagonCare Limited ASX : PGC
Slide 5: Disclaimer
Disclaimer Summary information This Presentation contains summary information about ParagonCare, and its activities current as at 21/11/2024. The information in the Presentation is of a general nature and does not purport to be complete or comprise all information which a shareholder or potential in
Slide 6: Peter Lacaze, Chairman: Welcome
Peter Lacaze Chairman Welcome AGM 21 November 2024
Slide 7: Acknowledgement of Country
Acknowledgement of Country In the spirit of reconciliation ParagonCare acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres St
Slide 8: Introduction: Board Directors
Introduction: Board Directors Peter Lacaze David Collins Chairman Chief Executive Officer Carmen Riley Alan McCarthy John Walstab Executive Director/ Non-Executive Director Executive Director and Executive General Chief Operating Officer Manager ParagonCare Asia AGM 21 November 2024
Slide 9: Format of Meeting
Format of Meeting 1. Chair Address 2. Questions and Voting Procedure 3. Formal Business 4. CEO Presentation 5. General Questions AGM 21 November 2024
Slide 10: Chair Address
Peter Lacaze Chairman Chair Address AGM 21 November 2024
Slide 11: Question & Voting Procedure
Question & Voting Procedure Annual General Meeting 2024 AGM 21 November 2024
Slide 12: Formal Business
Formal Business Annual General Meeting 2024 AGM 21 November 2024
Slide 13: Agenda Item: Receipt of financial statements and reports
Agenda Item 1 Receipt and consideration of financial statements & reports To receive and consider the financial report of the Company and the related reports of the Directors (including the Remuneration Report) and auditors for the financial year ended 30 June 2024. Further information Ernst & Young
Slide 14: Resolution 1: Adoption of Remuneration Report
Resolution 1 Adoption of Remuneration Report To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report (included in the Directors' Report) for the fina
Slide 15: Resolution 2: Re-election of Mr John Walstab
Resolution 2 Re-election of Mr John Walstab as a Director To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: ‘That Mr John Walstab, being a Director who retires by rotation pursuant to the Company’s Constitution and being eligible for re-election, be re-elected
Slide 16: Resolution 3: Re-election of Mr Alan McCarthy
Resolution 3 Re-election of Mr Alan McCarthy as a Director To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: ‘That Mr Alan McCarthy, being a Director who retires by rotation pursuant to the Company’s Constitution and being eligible for re-election, be re-elect
Slide 17: Resolution 4: Appointment of Auditor
Resolution 4 Appointment of Auditor To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That, for the purposes of section 327B of the Corporations Act and for all other purposes, Ernst & Young, having consented in writing to act in the capacity of auditor and b
Slide 18: Resolution 5: Renewal of Employee Incentive Plan
Resolution 5 Renewal of Paragon Care Limited Employee Incentive Plan To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That, under and for the purposes of Listing Rule 7.2 Exception 13(b), and for all other purposes including section 259B and 260C of the Corp
Slide 19: Resolution 6: Issue of Performance Rights to Ms Carmen Riley
Resolution 6 Issue of Performance Rights to Ms Carmen Riley To consider and, if thought fit, pass the following resolution as an ORDINARY resolution: “That, for the purposes of the purpose of Listing Rule 10.14 and for all other purposes, Shareholders approve the grant of Performance Rights to Ms Ca
Slide 20: Poll & Close of Formal Business
Poll & Close of Formal Business Annual General Meeting 2024 AGM 21 November 2024
Slide 21: David Collins, CEO Presentation
David Collins Chief Executive Officer CEO Presentation AGM 21 November 2024
Slide 22: Who are we
Who are we AGM 21 November 2024
Slide 23: Who are we
Who are we AGM 21 November 2024
Slide 24: 3 Businesses, 2 Years, 1 Team
3 Business 2 Years 1 Team 21 Investor update 22 June 2023
Slide 25: Strategic Overview
Strategic Overview Our Strategy Our Vision Diversified healthcare distributor Being the leading independent wholesaler & distributor in the Asia Pacific healthcare market by providing tailored solutions in leveraging ParagonCare’s comprehensive range, with a unique Pharmaceuticals, capital ParagonCa
Slide 26: ParagonCare completed the merger with CH2 in June 2024
ParagonCare completed the merger with CH2 in June 2024 - the combined entity offers a compelling value proposition to customers and supply partners An expanded product range for cross-selling and bundling A focus on operational efficiency, covering pharmaceutical, nutritional, medical quality servic
Slide 27: Business Development
Business Development Business Development - Category Management - Customer and Supplier Relationships Pharmacy Complimentary Medical Devices Capital & Cons Diagnostics Service Contract Medicine Consumables OEM Logistics Revenue: $2.5b Revenue: $100m Revenue: $419m Revenue: $23m Revenue: $239m Revenu
Slide 28: Focus on operational efficiency, quality service and competitive pricing
Focus on operational efficiency, quality service and competitive pricing The merged entity will benefit from cost synergies through network optimisation and the implementation of a shared services model Specific initiatives include: The consolidation of warehouse locations in Australia and the optim
Slide 29: Consolidating warehouse locations and expanding New Zealand and Asia
Consolidating to 8 warehouse locations in Australia and expanding New Zealand and Asia. Broad combined geographical reach Australia - New Zealand - Philippines - Thailand - Korea - Japan - Vietnam Planned expansion to Singapore, Malaysia and Indonesia
Slide 30: People, Diversity, Environment & Sustainability
People, Diversity, Environment & Sustainability Our greatest strength comes from our ingrained culture of “ONE TEAM” and building solid client and supplier relationships, maintaining open lines of communication, and delivering what we say we will do. ParagonCare We pride ourselves Our teams take per
Slide 31: New Mount Waverley facility to support sovereign manufacturing capability
New Mount Waverley facility to support sovereign manufacturing capability ParagonCare Diagnostics has a unique manufacturing and distribution capability through Immulab ParagonCare | Immulab manufactures immunohaematology In-Vitro Diagnostics, which are primarily used in Blood Banks. ParagonCare | I
Slide 32: Executing on the integration plan
Executing on the integration plan New Shared Designs for SMS and Oborne will be ISO14001 REM Balance of Engagement Organisational service Vision LabGear on fully integrated accreditation SYSTEMS Australia, Asia with all key structure in team merged: Australia now track for by end of by end of target
Slide 33: ParagonCare is a leading healthcare wholesaler, distributor & manufacturer
ParagonCare is a leading healthcare wholesaler, distributor & manufacturer* FY24 Proforma FY24 Proforma FY24 Proforma Revenue** EBITDA** Net Profit After Tax** $3.33 billion $90.8 million $28.4 million FY24 Statutory FY24 Statutory FY24 Statutory Revenue*** EBITDA*** Net Profit After Tax*** $2.97 bi
Slide 34: FY24 Balance Sheet: Statutory
FY24 Balance Sheet: Statutory Commentary $m FY24 FY23 Var $ Var % Receivables 350.6 209.9 115.3 54.9% Balance Sheet materially changed due to the CHS, Oborne acquisitions, and ParagonCare merger. Inventory 307.7 215.8 91.9 42.6% Working capital increase due to the strong revenue growth. Trade payabl
Slide 35: FY25 Outlook
FY25 Outlook Est Full Year CH2 up 31.4% Oct YTD % FY25 Run Growth $m CHS acquisition, market share FY24 gains, and GM GM % Growth Rate GM GM % Rate market growth. Pharmacy 2,491 90 3.6% 19.1% 2,825 99 3.5% 13.4% Medical Consumables 419 66 15.7% 5.4% 446 67 15.0% 6.5% Capital & Consumables OEM 239 93
Slide 36: FY25 Outlook
FY25 Outlook Continued execution on the integration plan for the merged entity. Increase cross-sell of expanded product range and bundled offerings. Focus on operational efficiency and cost rationalisation. Inaugural ParagonCare Annual Conference, with over 250 team members to reset strategy and foc
Slide 37: General Questions
General Questions Annual General Meeting 2024 AGM 21 November 2024
Slide 38: Thank you for joining us today
Thank you for joining us today